Phase I and pharmacokinetic study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously on days 1, 3, and 5 every 3 weeks in patients with …
C Cunningham, LJ Appleman, M Kirvan-Visovatti… - Clinical cancer …, 2005 - AACR
Purpose: To determine the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), and
pharmacokinetics of tasidotin (ILX651), a dolastatin-15 analogue, when administered on …
pharmacokinetics of tasidotin (ILX651), a dolastatin-15 analogue, when administered on …
A phase I study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously daily for 5 consecutive days every 3 weeks in patients with advanced solid …
S Ebbinghaus, E Rubin, E Hersh, LD Cranmer… - Clinical cancer …, 2005 - AACR
Purpose: To determine the maximum tolerated dose, dose-limiting toxicity, and
pharmacokinetics of the dolastatin-15 analogue, tasidotin (ILX651), when administered iv …
pharmacokinetics of the dolastatin-15 analogue, tasidotin (ILX651), when administered iv …
Phase I and pharmacokinetic study of tasidotin hydrochloride (ILX651), a third-generation dolastatin-15 analogue, administered weekly for 3 weeks every 28 days in …
AC Mita, LA Hammond, PL Bonate, G Weiss… - Clinical Cancer …, 2006 - AACR
Purpose: To determine the safety, tolerability, and pharmacokinetics and to seek preliminary
evidence of anticancer activity of tasidotin (ILX651), a novel dolastatin analogue, when …
evidence of anticancer activity of tasidotin (ILX651), a novel dolastatin analogue, when …
Phase I and pharmacokinetic study of the dolastatin 10 analogue TZT-1027, given on days 1 and 8 of a 3-week cycle in patients with advanced solid tumors
MJA de Jonge, A van der Gaast, AST Planting… - Clinical cancer …, 2005 - AACR
Abstract Purpose: TZT-1027 {N 2-(N, N-dimethyl-l-valyl)-N-[(1 S, 2 R)-2-methoxy-4-[(2 S)-2-
[(1 R, 2 R)-1-methoxy-2-methyl-3-oxo-3-[(2-phenylethyl)] amino] propyl]-1-pyrrolidinyl]-1-[(S) …
[(1 R, 2 R)-1-methoxy-2-methyl-3-oxo-3-[(2-phenylethyl)] amino] propyl]-1-pyrrolidinyl]-1-[(S) …
[HTML][HTML] Phase I and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1-hour intravenous infusion every 3 weeks in …
P Schöffski, B Thate, G Beutel, O Bolte, D Otto… - Annals of …, 2004 - Elsevier
Background TZT-1027 is a synthetic dolastatin 10 analog with antineoplastic properties in
various cell lines and tumor xenografts. The purpose of this phase I study was to evaluate …
various cell lines and tumor xenografts. The purpose of this phase I study was to evaluate …
Phase I and pharmacokinetic study of the water-soluble dolastatin 15 analog LU103793 in patients with advanced solid malignancies.
MA Villalona-Calero, SD Baker, L Hammond… - Journal of clinical …, 1998 - ascopubs.org
PURPOSE To determine the maximum-tolerated dose (MTD), dose-limiting toxicities (DLTs),
and pharmacokinetic profile of the dolastatin 15 analog LU103793 when administered daily …
and pharmacokinetic profile of the dolastatin 15 analog LU103793 when administered daily …
Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid …
K Tamura, K Nakagawa, T Kurata, T Satoh… - Cancer chemotherapy …, 2007 - Springer
Purpose To determine the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), and
pharmacokinetics of TZT-1027 (soblidotin), a dolastatin 10 analogue, in Japanese patients …
pharmacokinetics of TZT-1027 (soblidotin), a dolastatin 10 analogue, in Japanese patients …
Phase I study of TZT‐1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, given weekly to advanced solid tumor patients for 3 weeks
N Yamamoto, M Andoh, M Kawahara… - Cancer …, 2009 - Wiley Online Library
TZT‐1027 is a novel synthetic dolastatin 10 derivative that inhibits tubulin polymerization. A
phase I study was conducted to determine the maximum tolerated dose (MTD) of TZT‐1027 …
phase I study was conducted to determine the maximum tolerated dose (MTD) of TZT‐1027 …
Intracellular activation and deactivation of tasidotin, an analog of dolastatin 15: correlation with cytotoxicity
R Bai, MC Edler, PL Bonate, TD Copeland… - Molecular …, 2009 - ASPET
Tasidotin, an oncolytic drug in phase II clinical trials, is a peptide analog of the antimitotic
depsipeptide dolastatin 15. In tasidotin, the carboxyl-terminal ester group of dolastatin 15 …
depsipeptide dolastatin 15. In tasidotin, the carboxyl-terminal ester group of dolastatin 15 …
Preclinical analysis of tasidotin HCl in Ewing's sarcoma, rhabdomyosarcoma, synovial sarcoma, and osteosarcoma
V Garg, W Zhang, P Gidwani, M Kim, EA Kolb - Clinical cancer research, 2007 - AACR
Purpose: Dolastatins are a group of structurally unique peptides originally isolated from a
sea hare, Dolabella auricularia, which seem to inhibit tubulin polymerization and mitosis …
sea hare, Dolabella auricularia, which seem to inhibit tubulin polymerization and mitosis …